

#### SECONDARY TRADING NOTICE

Raiden Resources Limited (ASX: RDN) ('Raiden' or the 'Company') confirms that it has issued 21,000,000 fully paid ordinary shares at nil consideration ('Collateral Shares') to Acuity Capital Investment Management Pty Ltd (ACN 132 459 093) ('Acuity Capital') pursuant to the controlled placement agreement ('CPA') with Acuity Capital (see ASX announcement dated 2 July 2019).

The Collateral Shares were issued under the Company's 15% placement capacity under Listing Rule 7.1 as outlined in the Appendix 3B announced on the ASX platform on 22<sup>nd</sup> October 2019.

# Secondary Trading Notice (the 'Notice') Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 (the 'Act')

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Collateral Shares noted above will fall within exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) The Company has issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and;
- (c) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

#### **QUICK STATS**

**ASX Code: RDN** 

Shares on Issue: 431.4 million Market Cap: \$3.88 million Cash: \$1.75m (at 30 June '19)

#### **BOARD & MANAGEMENT**

Non- Executive Chairman
Mr Michael Davy

Managing Director Mr Dusko Ljubojevic

Non-Executive Directors
Mr Martin Pawlitschek

Company Secretary
Ms Kyla Garic

#### ASSET PORTFOLIO

Stara Planina - Serbia (JV with local entity – path to 100% -46km²)

Donje Nevlje - Serbia (100% – 74km²)

Majdanpek West - Serbia (Rio JV - 100% - 76km²)

**Zupa - Serbia** (100% Raiden – 85km²)

**Pirot - Serbia** (Executing Application – 16km²)

Bor – Serbia

(Partially granted/ pending application - 100% - ~28km²)

Vuzel - Bulgaria

(JV with local entity – path to 100%  $\sim$ 26.5 km<sup>2</sup>)

Kalabak - Bulgaria

(JV with local entity – path to  $75\% \sim 191$  km2)

Zlatusha - Bulgaria

(JV with local entity – path to  $75\% \sim 195$  km2)

Significant further ground holding currently under review.

#### **ASX RELEASE** | 22<sup>nd</sup> October 2019



As previously announced, the Company is continuing to review opportunities in the resource sector in line with the objective criteria set out by the Board. The Company advises that as at the date of this notice, it is undertaking negotiations and due diligence investigations into such potential project acquisition opportunities. These negotiations and investigations are incomplete and confidential and there can be no certainty that any agreement or agreements can be reached or that any transaction will eventuate. No binding commercial terms have been agreed between the parties. Accordingly, no investment decision should be made on the basis of this information. The Company will provide updates in accordance with its continuous disclosure obligations.

Yours faithfully,

Kyla Garic

**Company Secretary** 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $\begin{array}{l} Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13 \end{array}$ 

#### Name of entity RAIDEN RESOURCES LIMITED ABN 68 009 161 522 We (the entity) give ASX the following information. Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space). 1 1. Fully paid ordinary shares \*Class of \*securities issued or to be issued 21,000,000 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued Principal terms of the \*securities

Fully paid ordinary shares

+securities,

payment;

(e.g. if options, exercise price and expiry date; if partly paid

outstanding and due dates for

securities, the conversion price and dates for conversion)

if

the

amount

+convertible

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes, the fully ordinary shares will rank equally to the existing quoted fully paid ordinary shares.
5	Issue price or consideration	1. Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Controlled Shares issued pursuant to the Controlled Placement Facility with Acuity Capital, as announced on 2 July 2019
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A

<sup>+</sup> See chapter 19 for defined terms.

months from quotation

6f N/A Number of \*securities issued under an exception in rule 7.2 6g If \*securities issued under rule 7.1A, N/A was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. 6h If \*securities were issued under rule 7.1A for non-cash consideration, state on which valuation date of consideration was released to ASX **Market Announcements** 6i Calculate the entity's remaining issue 7.1-30,564,619 capacity under rule 7.1 and rule 7.1A -7.1 A - 41,043,080 complete Annexure 1 and release to ASX Market Announcements 7 22 October 2019 \*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number +Class 8 Number and \*class of all \*securities 322,880,796 Fully paid ordinary shares quoted on ASX (including \*securities in section 2 if applicable) 9 108,550,000 Number and +class of all +securities not Fully paid ordinary shares quoted on ASX (including the escrowed for 24 months +securities in section 2 if applicable) from quotation 5,375,000 A class performance shares B class performance 5,375,000 shares 6,450,000 C class performance shares 57,125,000 A class performance shares, escrowed for 24 months from quotation 57,125,000 B class performance shares, escrowed for 24

<sup>+</sup> See chapter 19 for defined terms.

	68,550,000	C class performance shares, escrowed for 24 months from quotation
	32,000,000	Unlisted options with exercise price of \$0.02 and expiring 3 years from issue date
	18,000,000	Unlisted options with exercise price of \$0.02 and expiring 3 years from issue date, escrowed for 24 months from quotation
	10,000,000	Performance rights subject to 20-day VWAP of \$0.02 or higher within 12 months from issue date
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
2 - Pro rata issue		
Is security holder approval required?	N/A	
Is the issue renounceable or non-renounceable?	N/A	
Ratio in which the *securities will be offered	N/A	
<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
<sup>+</sup> Record date to determine entitlements	N/A	
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	

10

11

12

13

14

15

16

Part 2 - Pro rata issue

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
	norders	
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
	meeting	
26	Data antitlament and according famous	N1/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

<sup>+</sup> See chapter 19 for defined terms.

30		do security holders sell their ements in full through a r?	N/A
31	their e	do security holders sell <i>part</i> of entitlements through a broker ccept for the balance?	N/A
32	their	do security holders dispose of entitlements (except by sale gh a broker)?	N/A
33	<sup>+</sup> Issue	e date	N/A
	-	otation of securities d only complete this section if you a	re applying for quotation of securities
34	Type of <sup>+</sup> securities (tick one)		
(a)	+Securities described in Part 1		
(b)			of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
Entitie	es tha	t have ticked box 34(a)	
Additi	onals	securities forming a new o	class of securities
Tick to	indicat	e you are providing the information	n or documents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for th	e additional <sup>+</sup> securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) 38 Number of \*securities for which N/A <sup>+</sup>quotation is sought 39 <sup>+</sup>Class of <sup>+</sup>securities for which N/A quotation is sought 40 N/A Do the \*securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation N/A now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other \*security) Number +Class 42 Number and +class of all +securities N/A N/A quoted on ASX (including the +securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
  - Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22.10.2019

(Company secretary)

Print name: Ms Kyla Garic.....

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	410,430,796	
Add the following:		
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	Nil	
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	Nil Nil	
Number of partly paid +ordinary securities that became fully paid in that 12 month period		
Note:		
Include only ordinary securities here –     other classes of equity securities cannot     be added		
Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	Nil	
"A"	410,430,796	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	61,564,619	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	10,000,000 (performance rights) 21,000,000 (ordinary shares)	
<ul> <li>Under an exception in rule 7.2</li> </ul>		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
Note:		
<ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> </ul>		
<ul> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
<ul> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	31,000,000	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	61,564,619	
Note: number must be same as shown in Step 2		
Subtract "C"	31,000,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	30,564,619	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	410,430,796	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	41,043,080	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
Notes:		
<ul> <li>This applies to equity securities – not just ordinary securities</li> </ul>		
<ul> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> </ul>		
It may be useful to set out issues of securities on different dates as separate line items		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	41,043,080	
Subtract "E"  Note: number must be same as shown in Step 3	Nil	
<i>Total</i> ["A" x 0.10] – "E"	41,043,080  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.